EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.36
+3.66%Oct 14, 2026, 12:30 UTC
Evolus entered into an option agreement with a privately held company developing an injectable hair-restoration treatment.
Source:Oct 2, 2026, 17:47 UTC
The U.S. Food and Drug Administration's Office of Prescription Drug Promotion issued a warning letter to Evolus Inc. in September over misleading Instagram promotional posts for its injectable drug Jeuveau.
Source:Oct 2, 2026, 14:24 UTC
The U.S. FDA sent a letter to Evolus, after which Evolus shares fell as much as 10%.
Source:Oct 1, 2026, 12:30 UTC
Evolus, Inc. launched Wings by Evolus, a new charitable platform uniting aesthetic practices, providers, and patients to support community causes, with its first initiative set for October in recognition of Breast Cancer Awareness Month.
Source:Aug 5, 2026, 20:05 UTC
Evolus, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting strong performance and its third consecutive quarter of positive adjusted EBITDA.
Aug 4, 2026, 12:30 UTC
Evolus expanded its partnership with Symatese by amending their licensing and distribution agreement to gain exclusive rights to commercialize the Estyme injectable hyaluronic acid gels in Canada, Australia, and New Zealand.
Source:Jul 10, 2026, 20:05 UTC
Evolus granted 115,000 restricted stock units to 38 newly hired non-executive employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
Source:Jul 8, 2026, 13:00 UTC
Evolus announced an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo in the United States.
Source: